Obedin-Maliver Juno, Snow Ava, Ragosta Sachiko, Fix Laura, Hastings Jen, Lubensky Micah E, Capriotti Matthew R, Dastur Zubin, Flentje Annesa, Lunn Mitchell R, Moseson Heidi
Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, United States; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, United States; The PRIDE Study/PRIDEnet, Stanford University School of Medicine, Palo Alto, CA, United States.
The PRIDE Study/PRIDEnet, Stanford University School of Medicine, Palo Alto, CA, United States.
Contraception. 2025 Jan;141:110719. doi: 10.1016/j.contraception.2024.110719. Epub 2024 Sep 26.
To describe contraceptive use for pregnancy prevention among transgender men and gender diverse (TGD) individuals assigned female or intersex at birth (AFIAB) and explore whether contraceptive use differs by testosterone use.
We analyzed data from a cross-sectional, online survey of N = 1694 TGD individuals AFIAB recruited in 2019 through a community-facing website and a national community-engaged cohort study of sexual and/or gender minority (SGM) adults in the US. Descriptive and regression analyses characterized the current and ever use of contraceptive methods for pregnancy prevention, stratified by testosterone use, and described reasons for contraceptive use/non-use.
Most respondents (71.0%) had used contraception before with 49.4% using it for pregnancy prevention. The methods that were most frequently ever used for pregnancy prevention included: external condoms (91.8%), combined hormonal contraceptive pills (63.0%), and withdrawal (45.9%). The methods most frequently currently used for pregnancy prevention included: external condoms (35.4%), hormonal intrauterine device (IUD) (24.8%), and abstinence (19.2%). Some reported formerly (n = 55, 6.6%) or currently (n = 30, 3.6%) relying on testosterone for pregnancy prevention. Only four of the 33 reasons for contraceptive use and non-use differed by testosterone use group. The most reported reasons for never using contraception were not engaging in penis-in-vagina sex (5.7%) or no sex with individuals who produce sperm (4.8%).
Most TGD individuals AFIAB have used contraception, and almost half for pregnancy prevention. The most used methods require minimal and/or non-invasive healthcare system interaction. Some respondents relied on testosterone as birth control, despite a lack of efficacy evidence.
TGD individuals use a range of birth control methods for pregnancy prevention and clinicians should not assume preferences for certain forms of contraception based on gender identity (e.g., estrogen avoidance). Clinicians should engage in patient-centered counseling and shared decision-making to provide high-quality contraceptive care to patients of all genders.
描述出生时被指定为女性或具有中间性特征的跨性别男性及性别多样化(TGD)个体预防怀孕的避孕措施使用情况,并探讨避孕措施的使用是否因睾酮使用情况而异。
我们分析了2019年通过一个面向社区的网站招募的1694名出生时被指定为女性或具有中间性特征的TGD个体的横断面在线调查数据,以及美国一项针对性和/或性别少数群体(SGM)成年人的全国社区参与队列研究数据。描述性和回归分析按睾酮使用情况分层,对预防怀孕的避孕方法的当前及既往使用情况进行了描述,并阐述了使用/不使用避孕措施的原因。
大多数受访者(71.0%)曾使用过避孕措施,其中49.4%用于预防怀孕。最常被用于预防怀孕的方法包括:外用避孕套(91.8%)、复方激素避孕药(63.0%)和体外排精(45.9%)。目前最常被用于预防怀孕的方法包括:外用避孕套(35.4%)、激素宫内节育器(IUD)(24.8%)和禁欲(19.2%)。一些人报告曾(n = 55,6.6%)或目前(n = 30,3.6%)依靠睾酮预防怀孕。在33个使用和不使用避孕措施的原因中,只有4个因睾酮使用组而异。最常被提及的从未使用避孕措施的原因是未进行阴茎插入阴道性交(5.7%)或未与能产生精子的个体发生性行为(4.8%)。
大多数出生时被指定为女性或具有中间性特征的TGD个体曾使用过避孕措施;近半数用于预防怀孕。最常使用的方法对医疗保健系统的干预要求最低和/或无创。一些受访者将睾酮作为节育手段,尽管缺乏有效性证据。
TGD个体使用多种避孕方法预防怀孕,临床医生不应基于性别认同(如避免使用雌激素)而假定患者对某些避孕方式有偏好。临床医生应开展以患者为中心的咨询并进行共同决策,为所有性别的患者提供高质量的避孕护理。